|
|
|
News
Check out our latest news

|
|
Cell>Point L.L.C. Preparing to
Conduct Studies — 10|1|02
HOUSTON, Texas - October 2002 - Cell>Point
L.L.C. is preparing to commence clinical
biokinetic and biodistribution studies at The
University of Texas M.D. Anderson Cancer Center
on 99mTc-EC-Metronidazole, 99mTc-EC-Annexin V
and 99mTc-EC-Cox-2. If results from the studies
are as expected, Cell>Point will prepare and
submit IND applications with the FDA for the
three "kit" compounds. 99mTc-EC-Metronidazole
will be studied as a tumor hypoxia marker,
99mTc-EC-Annexin V will be studied as a
programmed cell death marker and 99m Tc-EC-Cox-2
will be studied as a tumor marker.
Cell>Point is also preparing to commence
clinical biokinetic and biodistribution studies
on 99mTc-EC-Deoxyglucose for lymphoma. If
results from the study are as expected,
Cell>Point will prepare and submit an amendment
to its 99m Tc-EC-Deoxyglucose IND (63,698) to
include lymphoma as an additional indication.

|